Over 13,000 wireless phone chargers sold at T.J. Maxx and Marshalls have been recalled due to an explosion risk. “The ...

Cresco Labs CRLBF recently took a major strategic leap by announcing its entry into Germany — its first expansion outside the United States. The move marks a meaningful shift for a company that has ...

/Germany/EU Regulatory Notice: This communication is not intended for patients or the general public in Germany or the EU and does not constitute advertising for prescription-only medicinal products.

CHICAGO — Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced a strategic restructuring that includes plans to sell its California operations. This ...

CHICAGO, July 17, 2025--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) ("Cresco" or "Company"), the industry leader in branded cannabis products with a portfolio of America’s most ...

CHICAGO, June 12, 2025--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company"), today announced it has changed its ...

KINGSTON, N.Y. – Cresco Labs is describing the $20 million state fee for licensing as an “exorbitant upfront” impediment along with bureaucratic problems for its delay in getting the company’s ...

Today, Smiths Medical’s correction of the CADD-Solis Li-ion rechargeable battery packs was deemed FDA Class I. The CADD-Solis Li-ion rechargeable battery packs are lithium-ion battery packs used as an ...

'Cresco’s valuation metrics relative to its peers reflect a mismatch in the market's perception of its potential,' says analyst. Operating cash flow for the first half of 2024 reached $54 million, ...

Cannabis retailer Cresco Labs Inc. said Thursday its second-quarter loss widened on a $61 million charge related to its tax position, as revenue remained about flat. Cresco Labs CRLBF CA:CL said it ...

As societal attitudes and legislative landscapes regarding cannabis evolve, the potential for federal legalization looms. This shift, particularly if the drug's scheduling moves from Schedule I to ...